Download 2008 Registration Form

Download 2008 Poster

Download 2008 Brochure

Download Syllabus


7.00 - 7.25 - Registration and Continental Breakfast

7.25 - 7.30 - Introductory Remarks

7.30 - 9.30 - Management of Pancreatobiliary Malignancies

Paul Schultz and Giuseppe Aliperti
Pancreatic Surgeon:
Douglas Evans
Hepatobiliary Cancers:
Michael Choti
Robert Wolff
Frank Gress
David Carr-Locke

Points of Discussion:

  • Surgery in the management of patients with pancreatic cancer
    • Identifying patients who would benefit
    • Expected benefits and potential risks
    • Palliative surgery – is there any role now?
  • Surgery in the management of patients with bile duct cancer
    • Surgical options- resection vs transplant
    • Identifying patients who would benefit
    • Expected benefits
  • Role of chemotherapy ± radiation in management of patients with pancreatic and bile duct cancers
    • Resectable vs borderline resectable vs unresectable tumors
    • Expected benefits
    • Radiotherapy for unresectable pancreatic cancer - role
  • EUS and ERCP in the management of pancreatic cancer how recent advances can potentially help improve outcomes

9.30 - 9.45 - Coffee Break

9.45 - 11.15 - Minimally Invasive Procedures for Management of Gastrointestinal Cancers

Keith Naunheim and Eric Lederman
  1. Radiofrequency ablation for Barrett’s esophagus with HGD – Gregory Ginsberg
  2. Transanal endoscopic microsurgery - Dana Sands
  3. Minimally invasive esophagectomy - James Luketich
  4. Endoscopic stent placement - Todd Baron
  5. Laparoscopic pancreatectomy - Atilla Nakeeb

11.15 - 12.15 - Physicians and the Law

Banke Agarwal
Andrew Schlafly and Larry Huntoon

12.15-1.15 - Lunch

1.15 - 2.45 - Early Diagnosis of Pancreatic Cancer

Banke Agarwal and David Linehan
Suresh Chari
David Whitcomb
Michael Goggins
Maurits Wiersema

Points of Discussion:

  • Are there enriched patient subgroups in whom testing for pancreatic cancer may be useful?
  • Patients with genetic predisposition to pancreatic cancer- is early diagnosis possible in these patients with screening /surveillance programs?
  • Serum markers for pancreatic cancer- Are they realistic or just wishful thinking?
  • Does the advent of EUS make the screening/surveillance for pancreatic cancer more meaningful?

2.45 - 3.15 - State of the Art Lecture – Advances in Nuclear Medicine and its Impact on Diagnosis and Management of GI Cancers

Philip Alderson
Speaker Introduction by:
Medhat Osman

3.15 - 3.30 - Coffee Break  

3.30 - 5.00 - Post-Treatment Follow-up and Management of Recurrent GI Cancers

David Cort and Alex Denes

Intensive post-treatment; is it beneficial and worth the cost in patients with colorectal cancers?

Nancy Kemeny
Robert Fry

Post-treatment surveillance in patients with esophageal cancer; is it beneficial and worth the cost?

Edward Lin
Stephen Swisher

5.00 pm Conference Adjourned

ASGE designates this activity for a maximum of 8.0 AMA PRA Category 1
For additional information, call 314-977-7401.